Third, while we demonstrated anti-inflammatory effects through IL-6 measurement, future studies should include comprehensive cytokine profiling (IL-1β, TNF-α, MCP-1) to fully characterize M-SYFSF's immunomodulatory effects in DKD. Here, CCL2 is linked to diabetic kidney disease.